Zolpidem-induced sleepwalking, sleep related eating disorder, and sleep-driving: Fluorine-18-flourodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem

Journal of Clinical Sleep Medicine

Volumn 5, Issue 5, 2009, Pages 471-476

  Hoque, Romy ^a   Chesson Jr , Andrew L ^a  

^a Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

Fluorine 18 flourodeoxyglucose positron emission tomography; Sleep related eating disorder; Sleep driving; Sleepwalking; Zolpidem

Indexed keywords

FLUORODEOXYGLUCOSE F 18; ZOLPIDEM;

ADULT; ARTICLE; BEDTIME DOSAGE; CASE REPORT; HUMAN; INSOMNIA; MALE; POSITRON EMISSION TOMOGRAPHY; SLEEP DISORDER; SLEEP DRIVING; SLEEP RELATED EATING DISORDER; SLEEP WALKING;

EID: 70350518174     PISSN: 15509389     EISSN: 15509397     Source Type: Journal    
DOI: 10.5664/jcsm.27605     Document Type: Article

References (50)

1. American Academy of Sleep Medicine. The international classification of sleep disorders: diagnostic & coding manual. 2nd ed. Westchester, IL: American Academy of Sleep Medicine, 2005.
2. National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005. Sleep 2005;28:1049-1057
3. Ganzoni E, Santoni JP, Chevillard V, Sebille M, Mathy B. Zolpidem in insomnia: a 3-year post-marketing surveillance study in Switzerland. J Int Med Res 1995;23:61-73.
4. Sauvanet JP, Maarek L, Roger M, Renaudin J, Louvel E, Orofiamma B. Open long-term trials with zolpidem in insomnia. In: Sauvanet JP, Langer SZ, Morselli PL, eds. Imidazopyridines in sleep disorders. New York: Raven Press, 1988:339-349
5. Roehrs T, Vogel G, Vogel F, et al. Eligibility requirements in hypnotic trials. Sleep 1985;8:34-39 (Pubitemid 15110042)
6. Harrison NL. Mechanisms of sleep induction by GABA(A) receptor agonists. The J Clin Psychiatry 2007;68(Suppl 5):6-12.
7. Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 2000;59:865-889 (Pubitemid 30232327)
8. Langer SZ, Arbilla S, Scatton B, Niddam R, Dubois A. Receptors involved in the mechanism of action of zolpidem. In: Sauvanet JP, Langer SZ, Morselli PL, eds. Imidazopyridines in sleep disorders. New York: Raven Press, 1988:55-69.
9. Canaday BR. Amnesia possibly associated with zolpidem administration. Pharmacotherapy 1996;16:687-689 (Pubitemid 26285924)
10. Collis R. Hotels wake up to sleepwalking clients. 2007 [cited 2007 June 13, 2008]; Available from: http://www.iht.com/articles/2007/11/15/travel/ trfreq16.php
11. Pirker S, Schwarzer C, Wieselthaler A, Sieghart W, Sperk G. GABA(A) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Neuroscience 2000;101:815-850 (Pubitemid 30952906)
12. Dennis T, Dubois A, Benavides J, Scatton B. Distribution of central omega 1 (benzodiazepine1) and omega 2 (benzodiazepine2) receptor subtypes in the monkey and human brain. An autoradiographic study with [3H]flunitrazepam and the omega 1 selective ligand [3H]zolpidem. J Pharmacol Exp Ther 1988;247:309-322
13. Garretto NS, Bueri JA, Rey RD, Arakaki T, Nano GV, Mancuso M. Improvement of blepharospasm with Zolpidem. Mov Disord 2004;19:967-968
14. Evidente VG. Zolpidem improves dystonia in "Lubag" or X-linked dystonia-parkinsonism syndrome. Neurology 2002;58:662-663
15. Tassinari CA, Rubboli G, Gardella E, et al. Central pattern generators for a common semiology in fronto-limbic seizures and in parasomnias. A neuroethologic approach. Neurol Sci 2005;26 Suppl 3:s225-32.
16. Yuste R, MacLean JN, Smith J, Lansner A. The cortex as a central pattern generator. Nature Rev 2005;6:477-483
17. Gillin JC, Buchsbaum MS, Valladares-Neto DC, et al. Effects of zolpidem on local cerebral glucose metabolism during non- REM sleep in normal volunteers: a positron emission tomography study. Neuropsychopharmacology 1996;15:302-313
18. Buchsbaum MS, Hazlett EA, Wu J, Bunney WE Jr. Positron emission tomography with deoxyglucose-F18 imaging of sleep. Neuropsychopharmacology 2001;25(5 Suppl):S50-6. (Pubitemid 33000269)
19. Cohen L, Chaaban B, Habert MO. Transient improvement of aphasia with zolpidem. New Engl J Med 2004;350:949-950
20. Clauss RP, Nel WH. Effect of zolpidem on brain injury and diaschisis as detected by 99mTc HMPAO brain SPECT in humans. Arzneimittelforschung 2004;54:641-646
21. Clauss R, Sathekge M, Nel W. Transient improvement of spinocerebellar ataxia with zolpidem. New Engl J Med 2004;351:511-512 (Pubitemid 38988605)
22. Clauss RP, Dormehl IC, Oliver DW, Nel WH, Kilian E, Louw WK. Measurement of cerebral perfusion after zolpidem administration in the baboon model. Arzneimittelforschung 2001;51:619-622 (Pubitemid 32777671)
23. Clauss RP, Dormehl IC, Kilian E, Louw WK, Nel WH, Oliver DW. Cerebral blood perfusion after treatment with zolpidem and flumazenil in the baboon. Arzneimittelforschung 2002;52:740-744 (Pubitemid 35222022)
24. Brefel-Courbon C, Payoux P, Ory F, et al. Clinical and imaging evidence of zolpidem effect in hypoxic encephalopathy. Ann Neurol 2007;62:102-105 (Pubitemid 47240911)
25. May 2008 [cited; Available from: www.regentherapeutics.com
26. Chiang A, Krystal A. Report of two cases where sleep related eating behavior occurred with the extended-release formulation but not the immediate-release formulation of a sedative-hypnotic agent. J Clin Sleep Med 2008;4:155-156 (Pubitemid 352038656)
27. Roth T, Krystal AD, Maguire Y, Singh N, Maytom M. Pharmacokinetics of the sublingual zolpidem tartrate 3.5 mg lozenge compared to the oral zolpidem tartrate 10 mg tablet. Sleep 2008;31 (Abstract Supplement):A235.
28. Thomas P, Rascle C, Mastain B, Maron M, Vaiva G. Test for catatonia with zolpidem. Lancet 1997;349:702.
29. Wang WT, Chen YY, Wu SL, Wei TS, Liu SY. Zolpidem dramatically improved motor and speech function in a patient with central pontine myelinolysis. Eur J Neurol 2007;14:e9-10.
30. Tsai MJ, Tsai YH, Huang YB. Compulsive activity and anterograde amnesia after zolpidem use. Clin Toxicol (Philadelphia, PA) 2007;45:179-181
31. Jarry C, Fontenas JP, Jonville-Bera AP, Autret-Leca E. Beneficial effect of zolpidem for dementia. Ann Pharmacother 2002;36:1808.
32. Clauss RP, Guldenpfennig WM, Nel HW, Sathekge MM, Venkan- nagari RR. Extraordinary arousal from semi-comatose state on zolpidem. A case report. S Afr Med J 2000;90:68-72.
33. Clauss R, Nel W. Drug induced arousal from the permanent vegetative state. NeuroRehabilitation 2006;21:23-28 (Pubitemid 43754180)
34. Cohen SI, Duong TT. Increased arousal in a patient with anoxic brain injury after administration of zolpidem. Am J Phys Med Rehabil 2008;87:229-231
35. Shames JL, Ring H. Transient reversal of anoxic brain injury- related minimally conscious state after zolpidem administration: a case report. Arch Phys Med Rehabil 2008;89:386-388
36. Daniele A, Albanese A, Gainotti G, Gregori B, Bartolomeo P. Zolpidem in Parkinson's disease. Lancet 1997;349:1222-1223
37. Ruzicka E, Roth J, Jech R, Busek P. Subhypnotic doses of zolpidem oppose dopaminergic-induced dyskinesia in Parkinson's disease. Mov Disord 2000;15:734-735 (Pubitemid 30479630)
38. Farver DK, Khan MH. Zolpidem for antipsychotic-induced parkinsonism. Ann Pharmacother 2001;35:435-437
39. Daniele A, Moro E, Bentivoglio AR. Zolpidem in progressive supranuclear palsy. New Engl J Med 1999;341:543-544
40. Mayr BJ, Bonelli RM, Niederwieser G, Koltringer P, Reisecker F. Zolpidem in progressive supranuclear palsy. Eur J Neurol 2002;9:184-185 (Pubitemid 35013939)
41. Gericke CA, Ludolph AC. Chronic abuse of zolpidem. JAMA 1994;272:1721-1722
42. Bezerra ML, Martinez JV. Zolpidem in restless legs syndrome. Eur Neurol 2002;48:180-181
43. Mendelson WB. Sleepwalking associated with zolpidem. J Clin Psychopharmacol 1994;14:150.
44. Harazin J, Berigan TR. Zolpidem tartrate and somnambulism. Mil Med 1999;164:669-670
45. Morgenthaler TI, Silber MH. Amnestic sleep-related eating disorder associated with zolpidem. Sleep Med 2002;3:323-327
46. Sattar SP, Ramaswamy S, Bhatia SC, Petty F. Somnambulism due to probable interaction of valproic acid and zolpidem. Ann Pharmacother 2003;37:1429-1433 (Pubitemid 37205499)
47. Sharma A, Dewan VK. A case report of zolpidem-induced somnambulism. Primary care companion to J Clin Psychiatry 2005;7:74.
48. Najjar M. Zolpidem and amnestic sleep related eating disorder. J Clin Sleep Med 2007;3:637-638 (Pubitemid 350207109)
49. Sansone RA, Sansone LA. Zolpidem, somnambulism, and nocturnal eating. Gen Hosp Psychiatry 2008;30:90-91
50. Shadan FF, Poceta JS, Kline LE. Zolpidem for postanoxic spasticity. South Med J 2004;97:791-792